Jubilant Therapeutics Inc. verabreicht beim ersten Patienten die Dosis für die Phase I/II-Studie zur Untersuchung von JBI-802, einem dualen Inhibitor von LSD1 und HDAC6, bei Patienten mit fortgeschrittenen soliden Tumoren USA – English Deutschland – Deutsch
FOR FORMER ADDICTION PATIENTS NOW IN RECOVERY, RCA AT DEVON PROVIDES A LIFE – AND CAREER – CHANGING SECOND CHANCE
Sioux City Man With History of Violence Sentenced to 8 Years In Federal Prison for Illegally Possessing a Firearm
CBP Officers in Philadelphia, New York and Cincinnati Collaborate to Capture Cocaine Concealed in Cooler Cups